Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open-Label, Multi-Center Study of PDS0101 and Pembrolizumab (KEYTRUDA) Combination Immunotherapy in Subjects With Recurrent and/or Metastatic HNSCC and High-Risk HPV16 Infection

Next Previous
X
Search
Trial Profile

A Phase II, Open-Label, Multi-Center Study of PDS0101 and Pembrolizumab (KEYTRUDA) Combination Immunotherapy in Subjects With Recurrent and/or Metastatic HNSCC and High-Risk HPV16 Infection

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PDS 0101 (Primary) ; Pembrolizumab (Primary)
  • Indications Carcinoma; Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms VERSATILE-002
  • Sponsors PDS Biotechnology Corporation

    • Most Recent Events

    • 16 Sep 2024 According to a PDS Biotechnology Corporation Media Release, updated data from this study were presented at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain.
    • 16 Sep 2024 Updated results presented in a PDS Biotechnology Corporation Media Release.
    • 05 Aug 2024 According to a PDS Biotechnology Corporation media release, the data from this study has been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024 being held September 13-17, 2024, in Barcelona, Spain.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top